Literature DB >> 3190199

Hepatobiliary kinetics and excretion of ciprofloxacin.

M F Parry1, D A Smego, M A Digiovanni.   

Abstract

The biliary excretion and metabolism of ciprofloxacin was studied in 25 hospitalized patients: 19 undergoing routine cholecystectomy and 6 with indwelling biliary drainage catheters. An intravenous dose of 200 mg of ciprofloxacin given 2.5 to 3.0 h prior to cholecystectomy resulted in concentrations in common duct bile, gallbladder bile, and gallbladder wall of 5.69 +/- 4.8, 5.43 +/- 3.34, and 2.52 +/- 1.30 micrograms/g, respectively, all at least fourfold greater than simultaneous concentrations in serum. Ciprofloxacin concentrations in common duct bile exceeded peak concentrations in serum in all but two patients with common duct obstruction. Multiple preoperative doses of ciprofloxacin prior to cholecystectomy increased concentrations in gallbladder bile by eightfold. Six patients with indwelling biliary drainage catheters also received 200 mg of ciprofloxacin intravenously. Less than 1% of the administered dose was excreted in bile as unchanged ciprofloxacin, and there was extensive metabolism. However, peak ciprofloxacin concentrations of 2.83 +/- 0.76 micrograms/ml in serum produced peak concentrations of 10.69 +/- 5.30 micrograms/ml in bile within 1.5 h after infusion and maintained concentrations of at least 0.5 microgram/ml in common duct bile for over 12 h in all patients. It appears that ciprofloxacin concentrations in bile will exceed the MICs for most susceptible biliary pathogens for a period of at least 12 h after a 200-mg intravenous dose.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190199      PMCID: PMC172329          DOI: 10.1128/AAC.32.7.982

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.

Authors:  W Brumfitt; I Franklin; D Grady; J M Hamilton-Miller; A Iliffe
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

2.  Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers.

Authors:  R D Cofsky; L duBouchet; S H Landesman
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

3.  Biliary bacteria: significance and alterations after antibiotic therapy.

Authors:  H A Pitt; R G Postier; J L Cameron
Journal:  Arch Surg       Date:  1982-04

4.  The source of biliary infections associated with T-tube drainage.

Authors:  W A Agger; J E Glasser; W C Boyd; N Melby
Journal:  Infect Control       Date:  1983 Mar-Apr

5.  Antibiotics in biliary disease: the relative importance of antibiotic concentrations in the bile and serum.

Authors:  M R Keighley; R B Drysdale; A H Quoraishi; D W Burdon; J Alexander-Willians
Journal:  Gut       Date:  1976-07       Impact factor: 23.059

6.  Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.

Authors:  G Montay; Y Goueffon; F Roquet
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  Acute cholangitis.

Authors:  J H Boey; L W Way
Journal:  Ann Surg       Date:  1980-03       Impact factor: 12.969

8.  Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans.

Authors:  J M Brogard; F Jehl; H Monteil; M Adloff; J F Blickle; P Levy
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

Review 9.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

10.  Bacteriology of acute obstructive suppurative cholangitis of the aged.

Authors:  K Shimada; T Noro; T Inamatsu; K Urayama; K Adachi
Journal:  J Clin Microbiol       Date:  1981-11       Impact factor: 5.948

View more
  12 in total

1.  Influence of renal failure on intestinal clearance of ciprofloxacin in rats.

Authors:  S Dautrey; L Rabbaa; D Laouari; B Lacour; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

2.  Clinical efficacy of intravenous ciprofloxacin in patients with biliary tract infection: a randomized controlled trial with carbapenem as comparator.

Authors:  Susumu Tazuma; Yoshinori Igarashi; Toshio Tsuyuguchi; Hirotaka Ohara; Kazuo Inui; Toshihide Ohya
Journal:  J Gastroenterol       Date:  2009-05-23       Impact factor: 7.527

3.  Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.

Authors:  W L Hayton; V Vlahov; N Bacracheva; I Viachki; R Portmann; G Muirhead; K Stoeckel; E Weidekamm
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

4.  Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract.

Authors:  S J van den Hazel; X H de Vries; P Speelman; J Dankert; G N Tytgat; K Huibregtse; D J van Leeuwen
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

5.  Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells.

Authors:  Simon Lowes; Nicholas L Simmons
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

6.  Influence of renal failure on ciprofloxacin pharmacokinetics in rats.

Authors:  B Nouaille-Degorce; C Veau; S Dautrey; M Tod; D Laouari; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 7.  Quinolones and the gastrointestinal tract.

Authors:  B E Murray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

Review 8.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

9.  Is Ciprofloxacin a Substrate of P-glycoprotein?

Authors:  Miki Susanto Park; Hideaki Okochi; Leslie Z Benet
Journal:  Arch Drug Inf       Date:  2011-03

10.  Pharmacokinetic and pharmacodynamic interaction of Rosuvastatin calcium with guggulipid extract in rats.

Authors:  Mohammed Asad; Syed Mohammed Basheeruddin Asdaq; Yahya Mohzari; Ahmed Alrashed; Hamdan Najib Alajami; Awad Othman Aljohani; Abdullah Ali Al Mushtawi; Assil Najib Alajmi; Hanan Nageeb Alajmi; Mohd Imran; Raha Orfali
Journal:  Saudi J Biol Sci       Date:  2021-03-14       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.